サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426190

結合型モノクローナル抗体の世界市場レポート 2024

Conjugated Monoclonal Antibodies Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
結合型モノクローナル抗体の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

結合型モノクローナル抗体の市場規模は、今後数年間で大幅に成長すると予想されます。 2028年には6.3%の年間複合成長率（CAGR）で146億4,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、いくつかの重要な要因によって促進されると予想されます。これらには、ヘルスケアサービスへのアクセスの向上、低侵襲医療処置に対する需要の高まり、免疫療法の併用の探索、ヘルスケアへのアクセスの拡大、および治療の適応症の拡大が含まれます。

結合型モノクローナル抗体、特に抗体薬物複合体（ADC）の人気と治療の可能性の高まりにより、市場内の需要が高まると予測されています。 ADCは、抗原発現腫瘍細胞を標的とするリンカーを介して強力な細胞傷害性薬剤と結合したモノクローナル抗体で構成され、主にがん治療に使用されます。過去数年間に米国食品医薬品局が承認したADCは3つだけでしたが、特にがん治療における承認の増加と結合型モノクローナル抗体の適用との相関関係は、市場の成長軌道を裏付けています。

がんの蔓延は、結合型モノクローナル抗体市場の拡大の原動力となると予想されます。制御されていない異常な細胞増殖が腫瘍を形成することを特徴とするがんでは、これらの抗体が提供する標的を絞った正確な作用機序により、患者の生活の質が大幅に向上します。マクミランがんサポートは、がん症例数が徐々に増加し、2020年の300万人から2040年までに530万人と予測されると推定しています。この大幅ながん有病率は、結合型モノクローナル抗体市場の成長を促進する重要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の結合型モノクローナル抗体市場、医薬品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アドセトリス
  • カドサイラ
  • 世界の結合型モノクローナル抗体市場、技術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 切断可能なリンカー
  • 切断不可能なリンカー
  • 世界の結合型モノクローナル抗体市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 血液がん
  • 乳がん
  • 卵巣がん
  • 肺がん
  • 脳腫瘍
  • その他の用途

第7章 地域および国の分析

  • 世界の結合型モノクローナル抗体市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の結合型モノクローナル抗体市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 結合型モノクローナル抗体市場の競合情勢
  • 結合型モノクローナル抗体市場企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Bristol-Myers Squibb
    • Merck &Co. Inc.
    • Immunomedics Inc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r13212

Conjugated monoclonal antibodies refer to compounds resulting from chemically binding a medication to a monoclonal antibody. These antibodies specifically target proteins or receptors on particular cell types, such as cancer cells, allowing the associated medication to enter these cells, eliminate them, and spare healthy cells.

The primary drugs categorized as conjugated monoclonal antibodies are Adcetris and Kadcyla. Adcetris, a brand-name medication, is designed to treat specific forms of lymphoma in adults. Lymphoma is a type of cancer affecting the lymphatic system and lymphocytes, a type of white blood cell. These therapies utilize various technologies, including cleavable and non-cleavable linkers, and find application in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and other malignancies.

The conjugated monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides conjugated monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a conjugated monoclonal antibodies market share, detailed conjugated monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the conjugated monoclonal antibodies industry. The conjugated monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The conjugated monoclonal antibodies market size has grown strongly in recent years. It will grow from $10.9 billion in 2023 to $11.48 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historical period owes its momentum to several key factors. These include the rising incidence of cancer cases, the expansion of the private healthcare sector providing specialized treatments, governmental support initiatives, and the overall increase in the patient population seeking advanced medical care. These factors collectively contributed to the growth and development of therapies involving conjugated monoclonal antibodies during that time.

The conjugated monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $14.64 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The anticipated growth in the forecast period is expected to be driven by several significant factors. These include improved accessibility to healthcare services, heightened demand for minimally invasive medical procedures, the exploration of immunotherapeutic combinations, expanded healthcare accessibility, and the broadening of indications for treatments.

The rising popularity and therapeutic potential of conjugated monoclonal antibodies, specifically antibody-drug conjugates (ADCs), are projected to fuel demand within the market. ADCs, comprising monoclonal antibodies coupled with potent cytotoxic drugs through linkers to target antigen-expressing tumor cells, are primarily employed in cancer treatment. Despite the U.S. Food and Drug Administration approving only three ADCs in the past few years, the correlation between increased approvals and the application of conjugated monoclonal antibodies, particularly in cancer treatment, substantiates the market's growth trajectory.

The prevalence of cancer is anticipated to be a driving force behind the expansion of the conjugated monoclonal antibodies market. With cancer characterized by uncontrolled abnormal cell growth forming tumors, the targeted and precise mechanism of action offered by these antibodies significantly enhances the quality of life for patients. Macmillan Cancer Support estimates a progressive rise in cancer cases, from 3 million in 2020 to a projected 5.3 million by 2040. This substantial cancer prevalence is a key driver fueling growth in the market for conjugated monoclonal antibodies.

Leading firms operating in the realm of conjugated monoclonal antibodies are leveraging strategic partnerships to bolster their capabilities and offer comprehensive solutions. These partnerships entail companies leveraging each other's strengths and resources for mutual success. For example, in July 2023, BeiGene Ltd., a U.S.-based biotech firm, joined forces with Duality Biologics, a China-based clinical stage company, aiming to develop and commercialize a preclinical antibody-drug conjugate (ADC) therapy targeting specific solid tumors. The combined strengths of both entities are poised to expedite the development and market entry of this promising ADC therapy.

In June 2023 was indeed aimed at bolstering Lonza's capabilities in the development and manufacturing of antibody-drug conjugates (ADCs). The acquisition was focused on enhancing Lonza's ADC portfolio and gaining access to Synaffix's pipeline of ADC candidates. The specific financial details of the acquisition were not disclosed.

Major companies operating in the conjugated monoclonal antibodies market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., Spectrum Pharmaceuticals Inc., AbbVie Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Amgen, Celgene, Genentech, Emergent BioSolutions, Genzyme, Incyte Corporation, Kite Pharma, MorphoSys AG, Regeneron Pharmaceuticals, Seattle Genetics

North America was the largest region in the conjugated monoclonal antibody market in 2023. The Middle East is expected to be the fastest growing region in the global conjugated monoclonal antibodies market share during the forecast period. The regions covered in the conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The conjugated monoclonal antibodies market consists of sales of Brentuximab vedotin and Ado-trastuzumab emtansine. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Conjugated Monoclonal Antibodies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on conjugated monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for conjugated monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The conjugated monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drugs: Adcetris; Kadcyla
  • 2) By Technology: Cleavable Linker; Non-cleavable Linker
  • 3) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol -Myers Squibb; Merck & Co. Inc.; Immunomedics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Conjugated Monoclonal Antibodies Market Characteristics

3. Conjugated Monoclonal Antibodies Market Trends And Strategies

4. Conjugated Monoclonal Antibodies Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Conjugated Monoclonal Antibodies Market Size and Growth

  • 5.1. Global Conjugated Monoclonal Antibodies Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Conjugated Monoclonal Antibodies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Conjugated Monoclonal Antibodies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Conjugated Monoclonal Antibodies Market Segmentation

  • 6.1. Global Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Adcetris
  • Kadcyla
  • 6.2. Global Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cleavable Linker
  • Non-Cleavable Linker
  • 6.3. Global Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor
  • Other Applications

7. Conjugated Monoclonal Antibodies Market Regional And Country Analysis

  • 7.1. Global Conjugated Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Conjugated Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Conjugated Monoclonal Antibodies Market

  • 8.1. Asia-Pacific Conjugated Monoclonal Antibodies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Conjugated Monoclonal Antibodies Market

  • 9.1. China Conjugated Monoclonal Antibodies Market Overview
  • 9.2. China Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Conjugated Monoclonal Antibodies Market

  • 10.1. India Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Conjugated Monoclonal Antibodies Market

  • 11.1. Japan Conjugated Monoclonal Antibodies Market Overview
  • 11.2. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Conjugated Monoclonal Antibodies Market

  • 12.1. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Conjugated Monoclonal Antibodies Market

  • 13.1. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Conjugated Monoclonal Antibodies Market

  • 14.1. South Korea Conjugated Monoclonal Antibodies Market Overview
  • 14.2. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Conjugated Monoclonal Antibodies Market

  • 15.1. Western Europe Conjugated Monoclonal Antibodies Market Overview
  • 15.2. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Conjugated Monoclonal Antibodies Market

  • 16.1. UK Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Conjugated Monoclonal Antibodies Market

  • 17.1. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Conjugated Monoclonal Antibodies Market

  • 18.1. France Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Conjugated Monoclonal Antibodies Market

  • 19.1. Italy Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Conjugated Monoclonal Antibodies Market

  • 20.1. Spain Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Conjugated Monoclonal Antibodies Market

  • 21.1. Eastern Europe Conjugated Monoclonal Antibodies Market Overview
  • 21.2. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Conjugated Monoclonal Antibodies Market

  • 22.1. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Conjugated Monoclonal Antibodies Market

  • 23.1. North America Conjugated Monoclonal Antibodies Market Overview
  • 23.2. North America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Conjugated Monoclonal Antibodies Market

  • 24.1. USA Conjugated Monoclonal Antibodies Market Overview
  • 24.2. USA Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Conjugated Monoclonal Antibodies Market

  • 25.1. Canada Conjugated Monoclonal Antibodies Market Overview
  • 25.2. Canada Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Conjugated Monoclonal Antibodies Market

  • 26.1. South America Conjugated Monoclonal Antibodies Market Overview
  • 26.2. South America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Conjugated Monoclonal Antibodies Market

  • 27.1. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Conjugated Monoclonal Antibodies Market

  • 28.1. Middle East Conjugated Monoclonal Antibodies Market Overview
  • 28.2. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Conjugated Monoclonal Antibodies Market

  • 29.1. Africa Conjugated Monoclonal Antibodies Market Overview
  • 29.2. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Conjugated Monoclonal Antibodies Market Competitive Landscape And Company Profiles

  • 30.1. Conjugated Monoclonal Antibodies Market Competitive Landscape
  • 30.2. Conjugated Monoclonal Antibodies Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bristol -Myers Squibb
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Immunomedics Inc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Conjugated Monoclonal Antibodies Market Competitive Benchmarking

32. Global Conjugated Monoclonal Antibodies Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Conjugated Monoclonal Antibodies Market

34. Conjugated Monoclonal Antibodies Market Future Outlook and Potential Analysis

  • 34.1 Conjugated Monoclonal Antibodies Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Conjugated Monoclonal Antibodies Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Conjugated Monoclonal Antibodies Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer